Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the national cancer institute cooperative research and development studies

Oncologist

Volumn 6, Issue SUPPL. 2, 2001, Pages 22-28

  Murgo, Anthony J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Arsenic trioxide; Hematologic malignancy; National Cancer Institute; Solid tumor

Indexed keywords

ARSENIC TRIOXIDE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LYMPHOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; SOLID TUMOR; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CANCER;

EID: 0035041127     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_2-22     Document Type: Conference Paper

References (27)

1. 3 exerts dose-dependent dual effects on APL cells
2. Identification of genes regulated by the novel anti-tumor compound CT-2584
3. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo
4. Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells
5. Arsenic-interferon-α-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-κB activation
6. Involvement of the ceramide pathway in the cytotoxicity of arsenic trioxide and interferon alpha in HTLV-I transformed cells
7. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner
8. L
9. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations
10. Arsenic trioxide: An emerging therapy for multiple myloma
11. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
12. Arsenic trioxide is an equipotent inducer of apoptosis in androgen-dependent and androgen-independent LNCaP prostate cancer cell sublines
13. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression
14. Cytotoxicity of arsenic trioxide in cancer cell lines
15. 3) in the treatment of chronic myelogenous leukemia: In vitro and in vivo studies
16. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases
17. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells
18. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients
19. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms
20. Pharmacologic concentrations of arsenic trioxide induces growth inhibition and apoptosis in malignant lymphocytes and multiple myeloma cells
21. 2 family members
22. Arsenic trioxide: Rediscovery of a tumor cell-specific agent for the treatment of Ph+ leukemia
23. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines
24. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids
25. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines
26. Arsenic trioxide inhibits cell survival in a variety of cancer cell types
27. Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro